You are viewing the site in preview mode
Skip to main content
|
Screening method
|
NGS (cases)
|
Sensitivity (%)
|
Specificity (%)
|
PPV (%)
|
NPV (%)
|
|---|
|
LS-EC
|
Non-LS-EC
|
|---|
|
Total
|
6
|
105
| | | | |
|
Clinical criteria
| | |
33.3
|
88.6
|
14.3
|
95.9
|
|
Met
|
2
|
12
| | | | |
|
Unmet
|
4
|
93
| | | | |
|
IHC
| | |
66.7
|
75.0
|
33.3
|
100
|
|
MMR-deficient
|
4
|
24
| | | | |
|
MMR-intact
|
2
|
72
| | | | |
|
MSI
| | |
100.0
|
89.9
|
33.3
|
100.0
|
|
Positive
|
4
|
8
| | | | |
|
Negative
|
0
|
71
| | | | |
|
IHC plus MSI
| | |
100.0
|
72.4
|
20.0
|
100.0
|
|
MMR-deficient or MSI-positive
|
6
|
24
| | | | |
|
MMR-intact and MSI-negative
|
0
|
63
| | | | |
- Due to insufficient tumor tissues for examination, IHC was performed for only 102 patients, and MSI test was performed for 83 patients
- IHC: immunohistochemistry; MMR: mismatch repair; MSI: microsatellite instability; NGS: next-generation sequencing; LS-EC: Lynch syndrome-associated endometrial carcinoma; NPV: negative predictive value; PPV: positive predictive value
